Last reviewed · How we verify
NCT05501002
Pilot Study to Evaluate the CereVasc® EShunt® System in the Treatment of Communicating Hydrocephalus
NA trial testing eShunt® Implant in Hydrocephalus in 4 participants. Terminated before completion.
15 September 2023
Quick facts
| Lead sponsor | CereVasc Inc |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 4 |
| Start date | 15 September 2022 |
| Primary completion | 15 September 2023 |
| Estimated completion | 15 September 2023 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- eShunt® Implant
Conditions studied
- Hydrocephalus — all drugs for Hydrocephalus →
- Hydrocephalus, Communicating — all drugs for Hydrocephalus, Communicating →
Sponsor
CereVasc Inc — full company profile →
Who can join
21 and older, any sex, with Hydrocephalus or Hydrocephalus, Communicating. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study will be to evaluate a novel, minimally invasive method of treating hydrocephalus in adults. The eShunt® System includes a proprietary eShunt® Delivery System and the eShunt® Implant, a permanent implant that is deployed in a mildly invasive, neuro-interventional procedure. The eShunt® Implant is designed to drain excess cerebrospinal fluid (CSF) from the intracranial subarachnoid space (SAS) into the venous system.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A minimally invasive endovascular approach to the cerebellopontine angle cistern enables broad CNS biodistribution of scAAV9-CB-GFP.
Benatti HR, Anagnostakou V, Taghian T, Hall EF, et al · · 2024 · cited 4× · PMID 39192584 · DOI 10.1016/j.ymthe.2024.08.024
Verify or expand the search:
- PubMed search for NCT05501002
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hydrocephalus
Currently open trials in the same condition.
- NCT07478926 — Flow Detection in Open and Closed Shunt Valve Periods · NA · recruiting
- NCT07442929 — Crystallization of LA and Adjuvant Mixtures in Cerebrospinal Fluid · recruiting
- NCT06797219 — Light Therapy Device for Neonatal Intraventricular Hemorrhage Grade 3 and 4 · NA · recruiting
- NCT07380477 — VentricuLostomy AssoCiaTed InfeCtions (LACTIC): Focus on CSF Lactate and Sampling Site · recruiting
- NCT06276543 — Bactiseal Catheter Safety Registry Study · recruiting
Other CereVasc Inc trials
Trials by the same sponsor.
- NCT05232838 — US Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus · NA · active not recruiting
- NCT04758611 — The ETCHES I Study (Endovascular Treatment of Communicating Hydrocephalus With an Endovascular Shunt) · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05501002 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CereVasc Inc
- Last refreshed: 22 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05501002.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing